Heron Therapeutics (HRTX) Invested Capital: 2010-2025
Historic Invested Capital for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $14.9 million.
- Heron Therapeutics' Invested Capital rose 137.21% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 137.21%. This contributed to the annual value of -$33.7 million for FY2024, which is 0.95% up from last year.
- Heron Therapeutics' Invested Capital amounted to $14.9 million in Q3 2025, which was up 154.61% from -$27.3 million recorded in Q2 2025.
- In the past 5 years, Heron Therapeutics' Invested Capital registered a high of $196.2 million during Q1 2021, and its lowest value of -$40.0 million during Q3 2024.
- Over the past 3 years, Heron Therapeutics' median Invested Capital value was -$33.7 million (recorded in 2024), while the average stood at -$27.2 million.
- Per our database at Business Quant, Heron Therapeutics' Invested Capital slumped by 350.32% in 2023 and then soared by 137.21% in 2025.
- Over the past 5 years, Heron Therapeutics' Invested Capital (Quarterly) stood at $77.6 million in 2021, then plummeted by 82.50% to $13.6 million in 2022, then tumbled by 350.32% to -$34.0 million in 2023, then climbed by 0.95% to -$33.7 million in 2024, then spiked by 137.21% to $14.9 million in 2025.
- Its Invested Capital stands at $14.9 million for Q3 2025, versus -$27.3 million for Q2 2025 and -$28.5 million for Q1 2025.